Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.

Becton Dickinson announced on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its combination COVID-19, influenza A/B, and respiratory syncytial virus test.

A-share listed Sinocare issued a full-year performance forecast. The Company expects a significant rise in January-December 2022 results, net profit attributable to shareholders of the listed company is CNY 400 million to 460 million, net profit increased by 271.85% to 327.63% year-on-year.

The US Food and Drug Administration in January modified existing 510(k) clearances for several firms, including Becton Dickinson and Roche, while it granted new clearances for diagnostic instruments and assays from Medica, Selux Diagnostics, and others, according to the agency website.

Qiagen reported on Tuesday that its fourth quarter sales declined 14 percent with an expected decrease in COVID-related sales offset by increased sales in the firm's non-COVID portfolio.

Assure Tech released a full-year earnings forecast, in which the company expects its January-December 2022 results to rise sharply, with net profit attributable to shareholders of the listed company amounting to CNY 2.895 to 3.378 billion, a net profit increase of 292.06% to 357.40% year-on-year.

LumiraDx said Monday that it had nabbed US Food and Drug Administration Emergency Use Authorization and UK Health Security Agency Coronavirus Test Approvals process validation for LumiraDx's laboratory-based multiplex test for COVID-19 and influenza A and B.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.

BGI Genomics released the 2022 annual fiscal forecast. The operating revenue is expected to reach CNY 6.4 to 7.4 billion; the net profit attributable to shareholders of the listed companies is forecast to be CNY 800 million to 1.04 billion.

Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2023, ending December 31, 2022.